London-based PolyModels Hub has secured a £7 million Series A investment from Molten Ventures, in partnership with Marathon VentureCapital.
PolyModels Hub is a biotech software company developing the digital backbone for biopharma process development, reshaping how medicines are designed, developed, and manufactured. The company combines AI, advanced modelling, and data-driven workflows to help teams move faster from lab experiments to large-scale production.
Its flagship platform, ModelFlow, brings together process knowledge, models, simulation, and workflow management in a single environment. Scientists and engineers can design, test, and optimise drug processes more quickly and efficiently, helping organisations reduce time, cost, and risk while improving quality and compliance.
According to Antonio Benedetti, Co-founder and CEO of PolyModels Hub, the pharmaceutical sector is experiencing a major digital shift. He explains that the company’s technology and team have already demonstrated significant impact for large pharmaceutical partners within just 18 months, with these collaborations now expanding globally.
We’re investing deeply in complex biologics and advancing our platform to empower scientists with the model-based solutions they deserve to transform molecules into medicines for the 21st century.
With the latest investment, PolyModels Hub plans to grow its engineering and product teams, further develop its core platform, and reach more pharmaceutical companies globally.
The company will prioritise scalable solutions for process and regulatory workflows, supporting the broader digitalisation of biopharma process development and contributing to more efficient delivery of new medicines to patients.
Would you like to write the first comment?
Login to post comments